ArticleMovement disorders clinical practice2021
Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications.
Article in Movement disorders clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Plasma neurofilament light chain in early Parkinson's disease predicts motor complications: a prospective cohort study.NPJ Parkinson's disease · 2026Article
- The Correlation Between Apathy and the Efficacy of Rehabilitation in Patients With Parkinson's Disease: A Retrospective Observational Study.Brain and behavior · 2026Observational
- A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.Movement disorders clinical practice · 2026Review
- Prediction of impulse control disorders in Parkinson's disease through a longitudinal machine learning study.NPJ Parkinson's disease · 2026Article
- Identifying Risk Factors and Constructing Predictive Models for Wearing-Off and Dyskinesia in Chinese Patients With Parkinson's Disease on Long-Term Levodopa Therapy.CNS neuroscience & therapeutics · 2025Article
- The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis.The Lancet regional health. Europe · 2024Article
- Anxiety Change After Dopamine Therapy in Parkinson Disease is Independent of Motor Improvement.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2024Article
- Article
- Longitudinal faster anxiety progression ofFrontiers in neuroscience · 2024Article
- Impulsive-compulsive behaviour in early Parkinson's disease is determined by apathy and dopamine receptor D3 polymorphism.NPJ Parkinson's disease · 2023Article
- Barriers to home exercise for patients with Parkinson's disease: a qualitative study.BMJ open · 2023Article
- 'Anxious fluctuators' a subgroup of Parkinson's disease with high anxiety and problematic on-off fluctuations.Parkinsonism & related disorders · 2022Article
- Apathy in Parkinson's Disease: Defining the Park Apathy Subtype.Brain sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNeuropsychiatric and affective symptoms are prevalent in prodromal and clinical Parkinson's disease (PD). Some evidence suggests that they may also signify risk for motor complications (motor fluctuations and dyskinesias) of dopamine replacement therapy (DRT).
objectiveTo determine whether neuropsychiatric symptoms present in de novo PD (ie, before DRT initiation) predict the severity of eventual motor complications of DRT.
methodsWe used clinical, demographic, neurobehavioral, and neuroimaging data from the Parkinson's Progression Markers Initiative (PPMI), a multicenter observational PD study. Participants were unmedicated at enrollment and 361 initiated DRT during PPMI follow-up. We used Cox proportional hazard and multivariate ordinal mixed-effects regression models to evaluate the relationship between baseline neuropsychiatric symptoms and motor complications as measured by the Movement Disorders Society-revised Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
resultsThe cumulative incidences of dyskinesias and motor fluctuations during follow-up (6.0 ± 1.5 years) were 34.3% and 59.9%, respectively. Both apathy and high trait-anxiety (top quartile) conveyed over two-fold increases in hazard for dyskinesia onset and for adverse impact on activities of daily living caused by both dyskinesias and motor fluctuations. The longitudinal severity of motor fluctuations and dyskinesias was significantly predicted by baseline trait-anxiety and apathy, but not depression. Models were adjusted for dimensionally related symptoms (eg autonomic dysfunction) and potential confounding variables (eg DRT dose).
conclusionsApathy and anxiety levels in de novo PD may be neuropsychiatric biomarkers of vulnerability to earlier and more disabling motor complications of DRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.